Rheumatic Diseases: Pathophysiology, Targeted Therapy, Focus on Vascular and Pulmonary Manifestations
This e-book summarises the latest advances in the rheumatic diseases with a focus on the recent efforts of vascular and pulmonary manifestations and anticipate the new and future directions of these research topic. Rheumatic diseases represent a heterogeneous group of severe autoimmune disorders. Th...
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
| LEADER | 04250namaa2201045uu 4500 | ||
|---|---|---|---|
| 001 | doab80940 | ||
| 003 | oapen | ||
| 005 | 20220506 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 220506s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a 9783036536415 | ||
| 020 | |a 9783036536422 | ||
| 020 | |a books978-3-0365-3642-2 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-3642-2 |2 doi | |
| 040 | |a oapen |c oapen | ||
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a MKG |2 bicssc | |
| 720 | 1 | |a Ruaro, Barbara |4 edt | |
| 720 | 1 | |a Confalonieri, Paola |4 edt | |
| 720 | 1 | |a Confalonieri, Paola |4 oth | |
| 720 | 1 | |a Ruaro, Barbara |4 oth | |
| 720 | 1 | |a Salton, Francesco |4 edt | |
| 720 | 1 | |a Salton, Francesco |4 oth | |
| 245 | 0 | 0 | |a Rheumatic Diseases: Pathophysiology, Targeted Therapy, Focus on Vascular and Pulmonary Manifestations |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 online resource (178 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
| 520 | |a This e-book summarises the latest advances in the rheumatic diseases with a focus on the recent efforts of vascular and pulmonary manifestations and anticipate the new and future directions of these research topic. Rheumatic diseases represent a heterogeneous group of severe autoimmune disorders. The present Special Issue aims to provide an overview of the complexity of vascular and pulmonary manifestations of rheumatologic diseases and helps in knowledge to manage them. The eleven published articles here collected underline the complexity of rheumatic diseases and the difficult to treated them. The manuscripts provide an overview of the pathophysiology and current treatment regimes of these disorders, highlighting tools which assist with diagnosis, risk stratification and therapy. Finally, we underline the importance of a multidisciplinary team working using the skills of clinicians, radiologists, and pathologists. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine and Nursing |2 bicssc | |
| 650 | 7 | |a Pharmacology |2 bicssc | |
| 653 | |a 3D-echocardiography | ||
| 653 | |a airway disease | ||
| 653 | |a antifibrotic agents | ||
| 653 | |a cardiopulmonary exercise testing | ||
| 653 | |a connective tissue diseases | ||
| 653 | |a COVID-19 | ||
| 653 | |a CX3CL1/fractalkine | ||
| 653 | |a CX3CR1 | ||
| 653 | |a diffuse alveolar hemorrhage | ||
| 653 | |a efficacy | ||
| 653 | |a fibromyalgia | ||
| 653 | |a gastrointestinal symptoms | ||
| 653 | |a heart failure | ||
| 653 | |a high-resolution computed tomography | ||
| 653 | |a infection | ||
| 653 | |a inflammatory response | ||
| 653 | |a interstitial lung disease | ||
| 653 | |a interstitial lung diseases | ||
| 653 | |a IPF | ||
| 653 | |a M1 macrophage | ||
| 653 | |a M2 macrophage | ||
| 653 | |a microvascular involvement | ||
| 653 | |a nailfold capillaroscopy | ||
| 653 | |a osteopontin | ||
| 653 | |a outcome | ||
| 653 | |a pharmacological interactions | ||
| 653 | |a pleurisy | ||
| 653 | |a PMR | ||
| 653 | |a polymyalgia rheumatica | ||
| 653 | |a probiotic | ||
| 653 | |a progressive fibrosing ILD | ||
| 653 | |a pulmonary arterial hypertension | ||
| 653 | |a pulmonary function tests | ||
| 653 | |a pulmonary involvement | ||
| 653 | |a rheumatic | ||
| 653 | |a rheumatoid arthritis | ||
| 653 | |a scleroderma | ||
| 653 | |a shrinking lung syndrome | ||
| 653 | |a SKG mice | ||
| 653 | |a systemic lupus erythematosus | ||
| 653 | |a systemic sclerosis | ||
| 653 | |a t-vns | ||
| 653 | |a targeted therapy | ||
| 653 | |a tolerability | ||
| 653 | |a UIP | ||
| 653 | |a vagus nerve stimulation | ||
| 653 | |a ventricular function | ||
| 653 | |a ventricular-arterial coupling | ||
| 653 | |a VSL#3® | ||
| 793 | 0 | |a DOAB Library. | |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/80940 |7 0 |z Open Access: DOAB: description of the publication |
| 856 | 4 | 0 | |u https://mdpi.com/books/pdfview/book/5278 |7 0 |z Open Access: DOAB, download the publication |